Zacks Investment Research on MSN8h
Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More
It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...
Healthline15h
Compounded GLP-1s Helped Them Lose Weight, But New FDA Rule Could Block Access
The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain ...
Experimental women's cancer drug boosts survival rates in notable study
A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.
Investor's Business Daily on MSN2d
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
AstraZeneca said Monday its experimental pill lowered "bad" LDL cholesterol by 51%. The results showed promise again rival drugs from Merck and NewAmsterdam Pharma, but AstraZeneca stock fell in line ...
AstraZeneca’s potential blockbuster pill halves high cholesterol
AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...